Drugs used for COVID-19 treatment in pediatrics
an integrative review
DOI:
https://doi.org/10.51723/ccs.v31iSuppl%201.682Keywords:
2019-nCOV, COVID-19, SARS-CoV-2, PediatricsAbstract
An integrative review of studies recently published between January 1st and April 24th of 2020 was carried out, using the keywords: 2019-nCOV; COVID-19; SARS-CoV-2 and pediatrics. The PubMed, Períodicos CAPES, Science Direct, Scielo, Biblioteca Virtual em Saúde and Lilacs databases were searched. A total of 10 articles were considered eligible. Among the main therapeutic classes cited were antivirals lopinavir/ritonavir, oseltamivir, the use of interferon and immunoglobulins. Almost all the treatments mentioned were considered to be potentially effective against COVID-19, however clinical trials are necessary for such confirmation since there are few studies and the use of the mentioned drugs is based on the treatment of other respiratory diseases.
Downloads
References
Tezer H, Demirdağ T. Novel coronavirus disease (COVID-19) in children. Turkish Journal of Medical Sciences. 2020; 50: 592-603. https://doi.org/10.3906/sag-2004-174
Rothan H, Byrareddy S. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity. 2020; 109: 102433. https://doi.org/10.1016/j.jaut.2020.102433
Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. American Journal of Physiology-Endocrinology and Metabolism. 2020; 318 (5): 736-741.
Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 in Children — United States, February 12–April 2, 2020. Morbidity and Mortality Weekly Report, v.69, n. 14, 2020.
Brasil. Ministério Da Saúde. Coronavírus/Brasil. Painel Coronavírus. Disponível em: <https://covid.saude.gov.br/>. Acesso em 30 abr. 2020.
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Boletim Epidemiológico. COE Nº 11, Abr. 2020. Disponível em: https://www.saude.gov.br/images/pdf/2020/April/18/2020-04-17---BE11---Boletim-do-COE-21h.pdf .
Li Y, Guo F, Cao Y, Li L, Guo Y. Insight into COVID‐2019 for pediatricians. Pediatric Pulmonology. 2020; 55 (5).
Vaduganathan M, Vardeny O, Michel T, McMurray J, Pfeffer M, Solomon S. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. New England Journal of Medicine. 2020;382(17):1653-1659. https://doi.org/10.1056/NEJMsr2005760.
Yonker L, Shen K. Lessons unfolding from pediatric cases of COVID‐19 disease caused by SARS‐CoV‐2 infection. Pediatric Pulmonary. 2020; 55 (5): 1085-1086. https://doi.org/10.1002/ppul.24748
Calvo C, López-Hortelano M, Vicente J, Martínez J. Recommendations on the clinical management of the COVID-19 infection by the «new coronavirus» SARS-CoV2. Spanish Paediatric Association working group. Anales de Pediatría (English Edition). 2020.
Li Y, Guo F, Cao Y, Li L, Guo Y. Insight into COVID‐2019 for pediatricians. Pediatric Pulmonology. 2020;55(5).
Chiotos K, Hayes M, Kimberlin D, Jones S, James S, Pinninti S et al. Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. Journal of the Pediatric Infectious Diseases Society. 2020.
Sun D, Li H, Lu X, Xiao H, Ren J, Zhang F et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World Journal of Pediatrics. 2020. https://doi.org/10.1007/s12519-020-00354-4
Lu Q, Shi Y. Coronavirus disease (COVID‐19) and neonate: What neonatologist need to know. Journal of Medical Virology. 2020; 92 (6):564-567.
Chen Z, Fu J, Shu Q, Chen Y, Hua C, Li F et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World Journal of Pediatrics. 2020.
Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World Journal of Pediatrics. 2020. https://doi.org/10.1007/s12519-020-00343-7
Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19. The Pediatric Infectious Disease Journal. 2020;39 (5): 355-368. https://doi.org/ 10.1097/INF.0000000000002660
Rahimzadeh G, Ekrami Noghabi M, Kadkhodaei Elyaderani F, Navaeifar M, Enayati A, Manafi Anari A et al. COVID-19 Infection in Iranian Children: A Case Series of 9 Patients. Journal of Pediatrics Review. 2020:139-144.
Shen K, Yang Y. Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. World Journal of Pediatrics. 2020. https://doi.org/10.1007/s12519-020-00344-6
Devaux C, Rolain J, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. International Journal of Antimicrobial Agents. 2020; 105938.
Merino Argumánez C, Sáez de La Fuente I, Molina Collado Z, Suárez Pita D, Mestre Gómez B, Sanchez Izquierdo JA. La hidroxicloroquina, un fármaco potencialmente letal. Med Intensiva. 2017; 41: 257-259.
Poetker D, Reh D. A Comprehensive Review of the Adverse Effects of Systemic Corticosteroids. Otolaryngologic Clinics of North America. 2010;43(4):753-768. https://doi.org/10.1016/j.otc.2010.04.003
Kapoor A, Pandurangi U, Arora V, Gupta A, Jaswal A, Nabar A et al. Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society. Indian Pacing and Electrophysiology Journal. 2020.
Jin Y, Cai L, Cheng Z, Cheng H, Deng T, Fan Y et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military Medical Research. 2020;7(1).
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine. 2020.
Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 – an internet-based cross-sectional survey. Eurosurveillance. 2009; 14 (30).
Tullu MS. Oseltamivir. Journal of Postgraduate Medicine. 2009; 55 (3): 225-230. 10.4103/0022-3859.57411
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine. 2020.
Khalili J, Zhu H, Mak N, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. Journal of Medical Virology. 2020.
Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study. Clinical Microbiology and Infection. 2020.
Chandwani, A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Therapeutics and Clinical Risk Management. 2008; Volume 4: 1023-1033.
Downloads
Published
Issue
Section
License
Declaro para os devidos fins que o artigo que estou submetendo representa um trabalho original e nunca foi publicado total ou parcialmente, e que se alguma de suas partes foi publicada possuímos autorização expressa para a publicação no periódico Comunicação em Ciências da Saúde (CCS). Esse artigo não foi enviado a outro periódico e não o será enquanto estiver sendo considerada sua publicação; caso venha a ser aceito não será publicado em outro periódico; e não contém material difamatório ou ilegal sob nenhuma forma, não viola a intimidade de terceiros, nem infringe direitos protegidos.
Eu e demais autores desse trabalho certificamos por meio desta declaração que:
- Concordamos com as normas editoriais e com o processo de revisão da CCS;
- Aceitamos a responsabilidade pela conduta desse estudo e pela análise e interpretação dos dados;
- Cooperaremos, sempre que solicitado, na obtenção e fornecimento de dados sobre os quais o manuscrito está baseado, para exame dos avaliadores;
- Não estão sendo omitidos quaisquer ligações ou acordos de financiamento entre os autores e companhias ou pessoas que possam ter interesse no material abordado no artigo;
- Não estão sendo excluídos ou omitidos deste artigo autores ou instituições participantes;
- Possuímos permissão para uso de figuras e tabelas publicadas em outras fontes;
- Possuímos permissão das pessoas e instituições citadas nos agradecimentos;
- O autor correspondente autoriza a publicação do endereço informado e e-mail do(s) autor(es) junto com o artigo;
- Assumimos a responsabilidade pela entrega de documentos verídicos;
- Autorizamos a publicação do referido artigo no periódico Comunicação em Ciências da Saúde, segundo critérios próprios e em número e volume a serem definidos pelo editor do periódico;
- Nos comprometemos a atender os prazos estipulados pelos editores do periódico Comunicação em Ciências da saúde;
- Estamos cientes de que a não manifestação no prazo de dois dias da revisão da diagramação, recebida por e-mail, será considerado aprovado para publicação.
